PHATHOM PHARMACEUTICALS, INC. (PHAT) Free cash flow
- Free cash flow · 12 months (USD): Value $-36.91M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -15.40%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-36.91M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-36.69M − $219.00K ≈ $-36.91M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -15.40% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-36.91M ÷ $239.66M × 100 ≈ -15.40% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-36.69M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | -0.30× | Operating cash flow / net income. Period ending 2026-06-30. $-36.69M ÷ $121.95M ≈ -0.30× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -36.69M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 219.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -36.91M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 239.66M USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 121.95M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-36.91M | (m) | $-36.69M | $219.00K | (m) | $239.66M | (m) | $121.95M | (m) | (m) | -15.40% | -0.30× |
| 2026-03-31 | $-97.76M | (m) | $-97.49M | $272.00K | (m) | $204.89M | (m) | $63.73M | (m) | (m) | -47.71% | -1.53× |
| 2025-12-31 | $-167.00M | (m) | $-166.78M | $229.00K | (m) | $175.11M | (m) | $-221.25M | (m) | (m) | -95.37% | 0.75× |
| 2025-09-30 | $-225.38M | (m) | $-225.23M | $147.00K | (m) | $147.19M | (m) | $-274.55M | (m) | (m) | -153.12% | 0.82× |
| 2025-06-30 | $-274.85M | (m) | $-274.69M | $164.00K | (m) | $114.04M | (m) | $-330.15M | (m) | (m) | -241.02% | 0.83× |
| 2025-03-31 | $-282.79M | (m) | $-282.68M | $113.00K | (m) | $81.86M | (m) | $-345.79M | (m) | (m) | -345.46% | 0.82× |
| 2024-12-31 | $-266.90M | (m) | $-266.77M | $135.00K | (m) | $55.25M | (m) | $-334.33M | (m) | (m) | -483.07% | 0.80× |
| 2024-09-30 | $-247.72M | (m) | $-247.11M | $605.00K | (m) | $26.27M | (m) | $-339.44M | (m) | (m) | -942.96% | 0.73× |
| 2024-06-30 | $-216.95M | (m) | $-215.45M | $1.50M | (m) | $9.92M | (m) | $-297.11M | (m) | (m) | -2187.46% | 0.73× |
| 2024-03-31 | $-168.39M | (m) | $-166.93M | $1.46M | (m) | $2.59M | (m) | $-246.63M | (m) | (m) | -6491.56% | 0.68× |
| 2023-12-31 | $-139.21M | (m) | $-137.58M | $1.63M | (m) | $682.00K | (m) | $-201.59M | (m) | (m) | -20412.61% | 0.68× |
| 2023-09-30 | $-136.40M | (m) | $-134.82M | $1.57M | (m) | (m) | (m) | $-177.07M | (m) | (m) | (m) | 0.76× |
| 2023-06-30 | $-138.69M | (m) | $-137.93M | $766.00K | (m) | (m) | (m) | $-184.92M | (m) | (m) | (m) | 0.75× |
| 2023-03-31 | $-142.63M | (m) | $-141.44M | $1.19M | (m) | (m) | (m) | $-194.87M | (m) | (m) | (m) | 0.73× |
| 2022-12-31 | $-147.57M | (m) | $-146.53M | $1.04M | (m) | (m) | (m) | $-197.72M | (m) | (m) | (m) | 0.74× |
| 2022-09-30 | $-147.99M | (m) | $-147.26M | $729.00K | (m) | (m) | (m) | $-178.50M | (m) | (m) | (m) | 0.82× |
| 2022-06-30 | $-141.91M | (m) | $-141.31M | $609.00K | (m) | (m) | (m) | $-164.07M | (m) | (m) | (m) | 0.86× |
| 2022-03-31 | $-144.18M | (m) | $-143.95M | $226.00K | (m) | (m) | (m) | $-149.71M | (m) | (m) | (m) | 0.96× |
| 2021-12-31 | $-148.94M | (m) | $-148.62M | $328.00K | (m) | (m) | (m) | $-143.88M | (m) | (m) | (m) | 1.03× |
| 2021-09-30 | $-135.75M | (m) | $-135.40M | $352.00K | (m) | (m) | (m) | $-161.78M | (m) | (m) | (m) | 0.84× |
| 2021-06-30 | $-127.58M | (m) | $-127.06M | $521.00K | (m) | (m) | (m) | $-159.22M | (m) | (m) | (m) | 0.80× |
| 2021-03-31 | $-108.57M | (m) | $-108.04M | $533.00K | (m) | (m) | (m) | $-143.77M | (m) | (m) | (m) | 0.75× |
| 2020-12-31 | $-70.73M | (m) | $-69.69M | $1.04M | (m) | (m) | (m) | $-129.07M | (m) | (m) | (m) | 0.54× |
| 2020-09-30 | $-65.89M | (m) | $-64.87M | $1.02M | (m) | (m) | (m) | $-173.35M | (m) | (m) | (m) | 0.37× |
| 2020-06-30 | (m) | (m) | $-51.25M | (m) | (m) | (m) | (m) | $-207.36M | (m) | (m) | (m) | 0.25× |
| 2020-03-31 | (m) | (m) | $-47.12M | (m) | (m) | (m) | (m) | $-274.02M | (m) | (m) | (m) | 0.17× |
| 2019-12-31 | $-36.64M | (m) | $-36.51M | $132.00K | (m) | (m) | (m) | $-255.13M | (m) | (m) | (m) | 0.14× |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-89.79M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-2.29M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $-1.02M | (m) | (m) | (m) | (m) | $-1.29M | (m) | (m) | (m) | 0.79× |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |